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Abstract: The emerge of drug-resistant tuberculosis (TB) strain in recent decades is 
hampering the efforts of the international community to eliminate the disease worldwide. 
The World Health Organization (WHO) has drafted many strategies to achieve this ambitious 
goal. In the very beginning, the aim was to standardize inadequate regimens used in many 
countries and, thereafter, evolved to tackle the social determinants which hinder TB elimina-
tion. However, following the path of narrowing the clinical vision to deal with TB, there is an 
increased need to personalize the treatment considering both patients and pathogen unique 
characteristics. In our narrative review, we report the advantages and the backwards in 
developing a method to implement the concept of precision medicine to the treatment of 
TB. In this dissertation, we highlight the importance to address different aspects of the 
diseases encompassing the host and pathogen features, as well as the needs to further 
implement an adequate follow-up based on the available resources. Nevertheless, many 
things may hamper the vision of precision medicine in TB, such as the complexity and the 
costs to develop novel compounds and the costs related to global-scale implementation of 
patient-centered follow-up. To achieve the ambitious goal of TB elimination, a radical 
change in TB treatment is needed in order to give a more comprehensive approach based 
both on patients’ peculiarities and driven by drug susceptibility tests and whole-genome 
sequencing. 
Keywords: tuberculosis, drug-resistance, treatment, tailored, StopTB
Tuberculosis (TB) is the leading cause of death from a single microorganism. TB 
therapy is the outcome of several clinical studies.1,2 After the first therapeutic trials 
in the 40s’ and 50s’ aimed at evaluating single drugs which could reduce mortality 
rates and increase cure rates, it was clear that more than a single drug was needed to 
prevent the emergence of drug-resistant TB (DR-TB) strains. The next therapeutic 
challenge was to combine this goal with the reduction of the long treatment 
duration (ie, 12–24 months), which hindered patients’ adherence. The introduction 
of rifampicin in the 70s’ helped develop an effective short-course TB therapy for 
drug-susceptible (DS) forms.1 A standardized regimen for DS-TB is characterized 
by a 2-month intensive (bactericidal) phase with four drugs (isoniazid (H), rifam-
picin (R), ethambutol (E), and pyrazinamide (Z); 2HRZE) and a 4-month continua-
tion (sterilizing) phase with HR.
DR-TB forms can be classified in the following groups: (i) isoniazid-resistant TB 
(Hr-TB); (ii) rifampicin-resistant TB (RR-TB); multidrug-resistant TB (MDR-TB), 
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with mycobacterial strains resistant to at least isoniazid and 
rifampicin; pre-extensively-drug-resistant TB (pre-XDR- 
TB) with MDR mycobacterial strains resistant to fluoroqui-
nolones or injectable aminoglycosides; and XDR-TB with 
MDR mycobacterial strains resistant to both fluoroquino-
lones and aminoglycosides.2
New diagnostic tools that can rapidly detect DR pro-
files (ie, drug susceptibility tests [DSTs]) and TB drug 
research and development (R&D) could be key to tackle 
DR-TB and prevent further transmission of difficult-to- 
treat TB forms.
TB incident cases are 10 million annually worldwide, 
with 500,000 patients with DR-TB forms.1 Treatment suc-
cess for RR/MDR-TB forms (75%) is suboptimal and 
lower if compared with that achieved in DS forms 
(85%).2,3 Furthermore, a quarter of the world population 
is estimated to be infected by Mycobacterium tuberculosis 
(M.tb) and 11% (6 million people) is estimated to be 
infected with Hr-TB strains.
Interventions aimed at identifying at-risk subjects with 
latent infection and administering a preventative therapy 
can significantly change TB epidemiology.4,5
Tailoring regimens are key for DR-TB forms, prevent-
ing drug–drug interactions (DDIs) and drug-induced 
adverse events (AEs), which may reduce treatment success 
and completion rates. During the current decade, three new 
molecules were licensed for DR-TB: Bedaquiline (in 2012) 
(Bdq), Delamanid (in 2014) (Dlm), and Pretomanid (in 
2019) (PA-824 or Pa).6,7 WHO has recommended the pre-
scription of Bdq beyond 6 months of treatment, as well as 
during pregnancy, and in association with Dlm. Oral regi-
mens should be prescribed when feasible (eg, Bdq, Pa and 
Dlm)8
Ideally, successful treatment outcome can be improved 
prescribing effective drugs whose choice depends on DST 
and host biomarkers.6,9
Advantages of Precision TB 
Treatment
Tailoring Regimens: Achieving 
Individualized Cure While Minimizing 
Toxicity
In order to eliminate TB, treatment success needs to be 
ensured avoiding relapse in active TB and reactivation of 
LTBI.
From a patient point of view, to achieve this goal, TB 
treatment requires to be easily administrated to patients, by 
ensuring safety and tolerability when prescribed with other 
drugs, and as short as possible10,11 to enhance treatment 
compliance. Developing and implementing the use of pre-
dictive host-biomarkers – which provide information on 
the outcome based on a therapeutic intervention – could 
help improve treatment outcome rates.
Firstly, at-risk behaviors like unhealthy diet (eg fatty 
and fried foods may exacerbate drug-related liver toxicity), 
malnutrition, alcohol consumption, tobacco smoking, and 
substance abuse need to be investigated to prevent 
toxicity.12,13 Likewise, the clinician ought to explore the 
presence of any other co-morbidity (eg chronic obstructive 
pulmonary disease, HIV, diabetes mellitus) and possible 
ongoing treatment (eg anti-retroviral drugs, psychiatric 
medications, other concomitant antibiotic treatment). 
More importantly, because the initial treatment is always 
empirical clinicians should ask about a previous TB drug 
exposure to reduce the probabilities of unfavorable 
outcomes.
Ideally, clinicians would prefer to monitor anti-TB 
treatment by studying the pharmacokinetics/pharmacody-
namics of the drugs in blood samples to adequately 
adjust the dosage12,13 to maximize efficacy, prevent 
both relapse and undesired side-effects,9,14 and, conse-
quently, improve treatment completion. A helpful tool to 
measure blood drug concentrations in the blood at 
a given time is the therapeutic drug monitoring 
(TDM).15 For instance, linezolid exhibits a high rate of 
myelotoxicity and peripherals neuropathy at high 
dosages while it displays a desirable blood concentration 
between 2 and 7 mg/L where the majority of AEs are 
avoided in bacterial infections other than TB. The use of 
linezolid coupled with the implementation of an ade-
quate TDM sample timing immediately before the 
administration of the antibiotic may be helpful in adjust-
ing its dosage, thus preventing side effects of AEs.16,17 
Ideally, in the near future biologic samples, such as 
saliva, could be used to indirectly assess linezolid 
blood concentration to prevent preventable AEs.18 
Rapid turnaround of TDM helps to assess in real-time 
efficacy and/or prevent toxicity, giving a precious aid to 
clinicians in the choice of anti-TB treatments. The drugs 
which can benefit from TDM are reported in Table 1. Of 
note, TDM samples should be obtained correctly to 
minimize the risk of false-results due to inadequate sam-
pling (eg patient taking rifampicin the morning of pro-
grammed follow-up visits and wait over 2 hours before 
having the TDM blood sample).
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Moreover, in high-resource settings with, generally, 
low TB incidence a suitable approach to further enhance 
treatment completion by reducing AEs occurrence would 
consider patient’s genotype analysis. For example, poly-
morphisms in N-acetyltransferase (NAT) gene is thought 
to predict the occurrence of isoniazid-induced AEs, with 
low NAT activity (free isoform) linked to increased risk of 
hepatocellular impairment, mainly in individuals whose 
origin are from West Asia, South Asia, and South 
America.29 Likewise, the polymorphism of leukotriene 
A4 hydrolase (LTA4H), a key enzyme in the eicosanoid 
pathway, may predict an effective response in individuals 
from Asia; in fact, LTA4H activity may increase inflam-
mation, suggesting, then, an intensive use of steroids in TB 
meningitis. More studies are needed to confirm the role of 
LTA4H in modulating inflammation and TB response.30
The route of administration for anti-TB drugs – intra-
venous versus oral – depends mostly on disease’s severity, 
localization, absorption, and available drugs. As high-
lighted by the WHO, an all-oral 6–9-month regimen 
including Bdq, Pa, and linezolid (BPaL) may be prescribed 
in patients with pre-XDR-TB without any previous expo-
sure (<2 weeks of treatment) to Bdq and linezolid and 
under operational research circumstances.8 Nevertheless, 
in some cases, gastrointestinal absorption may be reduced, 
or oral administration may not feasible; hence, injectable 
agents could be alternatively administered while waiting to 
resolve the underlying cause.31,32
Finally, clinicians should investigate if patients have had 
any form of allergy, hypersensitivity or intolerance to what-
ever previous medicine. This will enable to reduce any 
preventable severe AE when tailoring anti-TB regimen.33
Pathogen-Related Variables
From a pathogen point of view, recent scientific advances 
have been achieved to improve the management of DR- 
Table 1 Proposed Therapeutic Drug Monitoring in DR-TB Tailored Regimens
Compounds Dosage Time for Sampling Desirable TDM 
Level (mg/L)
Reason
Isoniazid 300 mg die 2 hours post dose on empty stomach (every follow-up visit or in case 
of toxicity)
3–6 E/T
Rifampicin 600 mg die 2 hours post dose on empty stomach (every follow-up visit or in case 
of toxicity)
8–15 E/T
Pyrazinamide 25 mg/Kg 
(max 2500 mg) die
2 hours post dose on full or empty stomach (every follow-up visit or 
in case of toxicity)
20–60 E/T
Ethambutol 25 mg/Kg 
(max 1600 mg) die
2 and 6 hours post dose on full or empty stomach (every follow-up 
visit or in case of toxicity)
20–60 E
Levofloxacin max 1000 mg die 2 hours post dose on full or empty stomach (every follow-up visit or 
in case of toxicity)
8–12 E
Moxifloxacin max 800 mg die 2 hours post dose on full or empty stomach (every follow-up visit or 
in case of toxicity)
3–5 E
Clofazimine max 100 mg die 2 hours post dose on full or empty stomach (every follow-up visit or 
in case of toxicity)
0.5–4 T
Linezolid max 1200 mg die immediately before the dose (28 days or in case of toxicity) 2–7 T
Meropenem 
c.i.
max 6 g die during administration (every week) 8–12 E
Bedaquiline To be implemented E/T
Delamanid E/T
Pretomanid E/T
PAS E/T
Notes: Data from these studies.19–28  
Abbreviations: c.i., continuous infusion; E, efficacy; PAS, para-aminosalicylic acid; T, prevent toxicity; TDM, therapeutic drug monitoring.
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TB patients. Rapid molecular tools offer rapid resistance 
prediction compared to phenotypic DST. However, they 
allow prompt resistance prediction for several drugs and, 
by interrogating a limited part of genome, do not infer 
comprehensive drug susceptibility. Genome sequencing 
has indeed revolutionized and accelerated the progress 
toward tailored treatment for patients with DR-TB. By 
surveying the full “resistome” of Mycobacterium tubercu-
losis, the whole genome sequencing (WGS), offers the 
most comprehensive approach to determine resistance, 
predict susceptibility for few well-defined drug targets, 
and facilitate the timely design of individualized regi-
mens. However, the reliance on culture as an input for 
sequencing makes WGS implementation technically chal-
lenging in some setting as well as time consuming as it 
requires other 2–3 weeks. Targeted Next Generation 
Sequencing (NGS) represents an attractive alternative to 
perform multiple single target assays directly from spu-
tum, without waiting for colonies formation in culture 
media, and thus drastically reducing turnaround time to 
few days. Additional aspects such as phylogenetic lineage 
coupled with virulence and transmission properties are 
needed to move toward individualized regimen. In fact, 
although highly clonal, clinical Mycobacterium tuberculo-
sis strains have significant genetic diversity resulting in 
relevant impact on virulence, transmission and mutation 
rate.24,25 Despite NGS technologies are currently afford-
able, issues in the implementation (eg, infrastructure, 
human capacity, and data management) should be care-
fully considered.36
Therefore, together with DR profile, these additional 
aspects could significantly contribute to reducing treatment 
failure and build customized treatment.
The Follow-Up
Once the regimen for DR-TB has been tailored, efforts 
should be made to keep patients’ adherent to it. If the 
patient has been hospitalized, he/she should be discharged 
continuing the treatment as out-patients to avoid any 
further costs for the hospital.34 Then, follow-up visits, 
including a clinical, radiological and microbiological reas-
sessment, refill of the drugs used in his personalized anti- 
TB regimen, TDM of the drugs, blood-test should be 
performed to adjust the duration of the treatment. To 
enhance monitoring, clinicians should be able to track 
patients’ progress using electronic tools to increase adher-
ence and reduce dropouts.37,38 Medical examination and 
biochemical and microbiological results from the follow- 
up visit can be made available to the patient through 
mobile text message in order to stimulate adherence to 
treatment and to follow-up.39
According to the localization of the disease, time to 
culture conversion, radiological improvement, clinical sta-
bility and good tolerance to treatment, it is possible to 
forecast a shortening in DR-TB treatment.40,41
Challenges and Gaps in Providing 
Precision TB Treatment
The idea behind standardization in TB and LTBI treatment 
is to adequately and easily provide a proven effective 
therapy to anyone without waiting for DST results and 
regardless of socio-cultural setting and available resources 
in the country where they operate.
Going back to a heterogeneous landscape of anti-TB 
regimens will require the draft and dissemination of solid 
and complex guidelines by policy makers and national 
public health authorities. However, such guidelines need 
to be coupled with training of the medical staff – both 
specialists and general practitioner – to adequately tailor 
the treatment.
Tailoring treatment to either host and pathogen biomar-
kers requires the availability of novel compounds and their 
wide production and distribution. In recent years, as pre-
viously mentioned, three novel compounds have been 
developed after more than 30 years with no progress in 
pharmaceutical field.
The novel anti-TB drugs have been licensed by the 
Regulators (Food and Drugs Administration and European 
Medicines Agency) without completing the whole R&D 
process: Bdq was approved by FDA after a Phase 2 trial; 
Dlm was approved by EMA after a phase 2 trial; and, PA-824 
was approved by FDA after a phase 2b trial. Consequently, 
marketing authorization alone fails in made new compounds, 
or regimens, widely available to patients and clinicians 
because policy makers, which use the GRADE (Grading 
of Recommendations, Assessment, Development and 
Evaluation) methodology, are often unable to timely assess 
the effectiveness of a novel regimen due to stringent criteria 
adopted in clinical trials. Therefore, to tailor anti-TB treat-
ment a more agile and well-design R&D mechanism is 
mandatory.
CRISPR-based technologies may be a promising tool to 
expand TB drug pipeline. CRISPR-MTB test is under devel-
opment. However, shortcomings of the technology cannot 
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allow its point-of-care implementation, integrated into 
a compact desktop machine for a sample-in-result-out assay.40
Following the path marked by the oncology to custo-
mize the treatment; TB care is now facing a revolution of 
thought. To date, there are an increasing number of clinical 
trials using Bayesian adaptative randomization to rapidly 
select promising compounds concurrently requiring 
a smaller sample size. Nevertheless, there is a limited 
experience in applying those stratification algorithms, 
thus reducing confounding variables, in anti-TB drug 
development.41
From a pathogen’s biomarkers viewpoint, to use 
a more sophisticated method to rapidly and accurately 
predict drug susceptibility, for example, by using WGS 
and NGS technologies in clinical practice as well in 
clinical trials, further items are needed. Firstly, the cur-
rent nucleic acid amplification technologies (NAATs) (eg 
the cartridge Xpert MTB/RIF) due to their high sensitiv-
ity can detect nonviable bacilli leading to false-positive 
cases and unnecessary treatment, if used alone. Moreover, 
to use NAATs in drug R&D process as a surrogate end-
point further research and validation are needed to 
replace the current standard based on culture. However, 
NAATs can be implemented to assess the emerge of new 
forms of drug-resistance, and the genotypic profile asso-
ciated with it, when TB strains are exposed to a novel 
molecule during clinical trials thus concurrently develop-
ing a diagnostic tool to strengthen antimicrobial surveil-
lance systems if the compounds achieve the market 
approval.
Furthermore, tailoring anti-TB drug based on NAAT 
results will require, if novel drugs will be available, an 
increased expertise by clinician or the development to 
assist them when fashioning the regimen.
Assessing host biomarkers, however, will remain chal-
lenging mostly because patient’s willingness to disclose 
crucial information (eg alcohol intake) relies on the atti-
tude of clinician. TDM can be expensive and not always 
feasible; especially at district level where transportation 
issues to reference laboratories can affect its utility.
A patient-centered approach will also increase adherence 
throughout the whole duration of the treatment and should also 
be considered during clinical trials. By doing that healthcare 
workers should be trained to adequately conduct the treatment 
prescription and monitoring. Nevertheless, follow-up visits 
should not be too frequent in case patients living far distant 
to clinics with a lack of public transports or social protection to 
afford the travel expenditures. Finally, special at-risk groups, 
such as homelessness, people living in overcrowded houses, 
and pregnant women should be actively screened for both 
LTBI and active TB to decrease the burden of disease.
Conclusion
Even if the complexity and the costs to develop novel 
compounds as well as the difficulties in create dedicated 
centers for DR-TB diagnosis and treatment worldwide 
may slow-down the path to tailored anti-TB treatment, to 
achieve the ambitious goal of TB elimination, a radical 
change in TB treatment, in order to give a more compre-
hensive approach based both on patients’ peculiarities and 
driven by DST and WGS, is needed.
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